# Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

> **NCT04609566** · PHASE2 · COMPLETED · sponsor: **Seagen, a wholly owned subsidiary of Pfizer** · enrollment: 161 (actual)

## Conditions studied

- Melanoma
- Non-small Cell Lung Cancer
- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** brentuximab vedotin
- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT04609566
- **Lead sponsor:** Seagen, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-26
- **Primary completion:** 2026-02-03
- **Final completion:** 2026-02-03
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04609566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04609566, "Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04609566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*